211 related articles for article (PubMed ID: 21044016)
1. Novel role of NPC1L1 in the regulation of hepatic metabolism: potential contribution of ezetimibe in NAFLD/NASH treatment.
Yoshida M
Curr Vasc Pharmacol; 2011 Jan; 9(1):121-3. PubMed ID: 21044016
[TBL] [Abstract][Full Text] [Related]
2. Ezetimibe as a potential treatment for non-alcoholic fatty liver disease: is the intestine a modulator of hepatic insulin sensitivity and hepatic fat accumulation?
Ahmed MH; Byrne CD
Drug Discov Today; 2010 Aug; 15(15-16):590-5. PubMed ID: 20601094
[TBL] [Abstract][Full Text] [Related]
3. The Niemann-Pick C1 like 1 (NPC1L1) inhibitor ezetimibe improves metabolic disease via decreased liver X receptor (LXR) activity in liver of obese male mice.
Sugizaki T; Watanabe M; Horai Y; Kaneko-Iwasaki N; Arita E; Miyazaki T; Morimoto K; Honda A; Irie J; Itoh H
Endocrinology; 2014 Aug; 155(8):2810-9. PubMed ID: 24773344
[TBL] [Abstract][Full Text] [Related]
4. Inhibition of intestinal cholesterol absorption by ezetimibe is a novel therapeutic target for fatty liver.
Yamagishi S; Nakamura K; Matsui T; Sato T; Takeuchi M
Med Hypotheses; 2006; 66(4):844-6. PubMed ID: 16188393
[TBL] [Abstract][Full Text] [Related]
5. Ezetimibe restores biliary cholesterol excretion in mice expressing Niemann-Pick C1-Like 1 only in liver.
Tang W; Jia L; Ma Y; Xie P; Haywood J; Dawson PA; Li J; Yu L
Biochim Biophys Acta; 2011 Sep; 1811(9):549-55. PubMed ID: 21683156
[TBL] [Abstract][Full Text] [Related]
6. Niemann-pick C1-like 1 (NPC1L1) protein in intestinal and hepatic cholesterol transport.
Jia L; Betters JL; Yu L
Annu Rev Physiol; 2011; 73():239-59. PubMed ID: 20809793
[TBL] [Abstract][Full Text] [Related]
7. Pathophysiological importance of bile cholesterol reabsorption: hepatic NPC1L1-exacerbated steatosis and decreasing VLDL-TG secretion in mice fed a high-fat diet.
Toyoda Y; Takada T; Yamanashi Y; Suzuki H
Lipids Health Dis; 2019 Dec; 18(1):234. PubMed ID: 31883528
[TBL] [Abstract][Full Text] [Related]
8. NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease.
Enjoji M; Machida K; Kohjima M; Kato M; Kotoh K; Matsunaga K; Nakashima M; Nakamuta M
Lipids Health Dis; 2010 Mar; 9():29. PubMed ID: 20222991
[TBL] [Abstract][Full Text] [Related]
9. Hepatic Niemann-Pick C1-like 1.
Pramfalk C; Jiang ZY; Parini P
Curr Opin Lipidol; 2011 Jun; 22(3):225-30. PubMed ID: 21494140
[TBL] [Abstract][Full Text] [Related]
10. Inhibition of hepatic Niemann-Pick C1-like 1 improves hepatic insulin resistance.
Nomura M; Ishii H; Kawakami A; Yoshida M
Am J Physiol Endocrinol Metab; 2009 Nov; 297(5):E1030-8. PubMed ID: 19654286
[TBL] [Abstract][Full Text] [Related]
11. Ezetimibe inhibits hepatic Niemann-Pick C1-Like 1 to facilitate macrophage reverse cholesterol transport in mice.
Xie P; Jia L; Ma Y; Ou J; Miao H; Wang N; Guo F; Yazdanyar A; Jiang XC; Yu L
Arterioscler Thromb Vasc Biol; 2013 May; 33(5):920-5. PubMed ID: 23471229
[TBL] [Abstract][Full Text] [Related]
12. Ezetimibe improves liver steatosis and insulin resistance in obese rat model of metabolic syndrome.
Deushi M; Nomura M; Kawakami A; Haraguchi M; Ito M; Okazaki M; Ishii H; Yoshida M
FEBS Lett; 2007 Dec; 581(29):5664-70. PubMed ID: 18022391
[TBL] [Abstract][Full Text] [Related]
13. Cardiovascular Risk Reduction in Patients with Nonalcoholic Fatty Liver Disease: The Potential Role of Ezetimibe.
Simon TG; Corey KE; Chung RT; Giugliano R
Dig Dis Sci; 2016 Dec; 61(12):3425-3435. PubMed ID: 27714510
[TBL] [Abstract][Full Text] [Related]
14. Is the control of dietary cholesterol intake sufficiently effective to ameliorate nonalcoholic fatty liver disease?
Enjoji M; Nakamuta M
World J Gastroenterol; 2010 Feb; 16(7):800-3. PubMed ID: 20143458
[TBL] [Abstract][Full Text] [Related]
15. Multiple plasma membrane receptors but not NPC1L1 mediate high-affinity, ezetimibe-sensitive cholesterol uptake into the intestinal brush border membrane.
Knöpfel M; Davies JP; Duong PT; Kvaernø L; Carreira EM; Phillips MC; Ioannou YA; Hauser H
Biochim Biophys Acta; 2007 Sep; 1771(9):1140-7. PubMed ID: 17689140
[TBL] [Abstract][Full Text] [Related]
16. Ezetimibe improves high fat and cholesterol diet-induced non-alcoholic fatty liver disease in mice.
Zheng S; Hoos L; Cook J; Tetzloff G; Davis H; van Heek M; Hwa JJ
Eur J Pharmacol; 2008 Apr; 584(1):118-24. PubMed ID: 18329014
[TBL] [Abstract][Full Text] [Related]
17. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe.
Temel RE; Tang W; Ma Y; Rudel LL; Willingham MC; Ioannou YA; Davies JP; Nilsson LM; Yu L
J Clin Invest; 2007 Jul; 117(7):1968-78. PubMed ID: 17571164
[TBL] [Abstract][Full Text] [Related]
18. Hepatic Expression of Niemann-Pick C1-Like 1, a Cholesterol Reabsorber from Bile, Exacerbates Western Diet-Induced Atherosclerosis in LDL Receptor Mutant Mice.
Yamamoto H; Yamanashi Y; Takada T; Mu S; Tanaka Y; Komine T; Suzuki H
Mol Pharmacol; 2019 Jul; 96(1):47-55. PubMed ID: 31064810
[TBL] [Abstract][Full Text] [Related]
19. Flotillins play an essential role in Niemann-Pick C1-like 1-mediated cholesterol uptake.
Ge L; Qi W; Wang LJ; Miao HH; Qu YX; Li BL; Song BL
Proc Natl Acad Sci U S A; 2011 Jan; 108(2):551-6. PubMed ID: 21187433
[TBL] [Abstract][Full Text] [Related]
20. NPC1L1 and cholesterol transport.
Betters JL; Yu L
FEBS Lett; 2010 Jul; 584(13):2740-7. PubMed ID: 20307540
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
